BACKGROUND: The impact of coronavirus disease 2019 (COVID-19) in haematological patients (HP) has not been comprehensively reported. METHODS: We analysed 39 patients with SARS-CoV-2 infection and haematological malignancies. Clinical characteristics and outcomes were compared to a matched control group of 53 non-cancer patients with COVID-19. Univariate and multivariate analyses were carried out to assess the risk factors associated with poor outcome. RESULTS: The most frequent haematological diseases were lymphoma (30%) and multiple myeloma (30%). Eighty-seven % HP developed moderate or severe disease. Patients with haematological malignancies had a significantly higher mortality rate compared to non-cancer patients (35.9% vs 13.2%; P = .003 (odds ratio 6.652). The worst outcome was observed in chronic lymphocytic leukaemia patients. Only age >70 years and C reactive protein >10 mg/dl at admission were associated with higher risk of death (odds ratio 34.86, P = .003 and 13.56,P = .03). Persistent viral sheddind was detected in 5 HP. Active chemotherapy, viral load at diagnosis and COVID-19 therapy were not predictors of outcome. CONCLUSION: Mortality of COVID-19 is significantly higher in patients with haematological malignancies compared to non-cancer patients. The impact of persistent viral shedding must be considered in order to re-start therapies and maintain infectious control measures.
BACKGROUND: The impact of coronavirus disease 2019 (COVID-19) in haematological patients (HP) has not been comprehensively reported. METHODS: We analysed 39 patients with SARS-CoV-2 infection and haematological malignancies. Clinical characteristics and outcomes were compared to a matched control group of 53 non-cancerpatients with COVID-19. Univariate and multivariate analyses were carried out to assess the risk factors associated with poor outcome. RESULTS: The most frequent haematological diseases were lymphoma (30%) and multiple myeloma (30%). Eighty-seven % HP developed moderate or severe disease. Patients with haematological malignancies had a significantly higher mortality rate compared to non-cancerpatients (35.9% vs 13.2%; P = .003 (odds ratio 6.652). The worst outcome was observed in chronic lymphocytic leukaemia patients. Only age >70 years and C reactive protein >10 mg/dl at admission were associated with higher risk of death (odds ratio 34.86, P = .003 and 13.56,P = .03). Persistent viral sheddind was detected in 5 HP. Active chemotherapy, viral load at diagnosis and COVID-19 therapy were not predictors of outcome. CONCLUSION:Mortality of COVID-19 is significantly higher in patients with haematological malignancies compared to non-cancerpatients. The impact of persistent viral shedding must be considered in order to re-start therapies and maintain infectious control measures.
Authors: A Oliva; A Curtolo; L Volpicelli; F Cancelli; C Borrazzo; F Cogliati Dezza; G Marcelli; F Gavaruzzi; S Di Bari; P Ricci; O Turriziani; C M Mastroianni; M Venditti Journal: Infection Date: 2022-07-03 Impact factor: 7.455
Authors: Anup S Pathania; Philip Prathipati; Bakrudeen Aa Abdul; Srinivas Chava; Santharam S Katta; Subash C Gupta; Pandu R Gangula; Manoj K Pandey; Donald L Durden; Siddappa N Byrareddy; Kishore B Challagundla Journal: Theranostics Date: 2021-01-01 Impact factor: 11.600
Authors: Marcial Delgado-Fernández; Gracia Mar García-Gemar; Ana Fuentes-López; Manuel Isidro Muñoz-Pérez; Salvador Oyonarte-Gómez; Ignacio Ruíz-García; Jessica Martín-Carmona; Jaime Sanz-Cánovas; Manuel Ángel Castaño-Carracedo; José María Reguera-Iglesias; Juan Diego Ruíz-Mesa Journal: Enferm Infecc Microbiol Clin (Engl Ed) Date: 2021-02-11